by Kevin Robb | Aug 22, 2024
Last month, the U.S. Food and Drug Administration (FDA) agreed to formally review a revised Biologics License Application (BLA) from Mesoblast for their mesenchymal stromal cell (MSC) product, remestemcel-L. The submission represents the third attempt by the company...
by Lyla El-Fayomi | Jun 18, 2024
“Regenerative medicine news under the microscope” is a monthly feature highlighting a selection of impactful research findings and headlines across the many subfields of regenerative medicine. Throughout the past month, I’ve spotted some notable trends emerging in the...
by Laine Bodnar | Jun 12, 2024
Have you wondered how many cell and gene therapies (CGTs) have been approved in Canada? So did I. To track the number down, I first turned to my trusty internet search engine with hopes that a list of Health Canada-approved CGTs would already exist online. Notably, it...
by Stacey Johnson | Feb 2, 2024
If you have finally recovered from Advanced Therapies Week (ATW) 2024, don’t get too comfortable since the website for ATW 2025, to be held in San Diego, California, is already published. It’s worth visiting as it features some nice photos of this year’s event to...
by Cal Strode | Jan 18, 2024
About a year ago today, I covered the 2023 Alliance for Regenerative Medicine (ARM) State of the Industry Briefing for Signals. The briefing placed strong emphasis on the industry’s acceleration, driven by scientific advances that are bringing meaningful developments...
by Stacey Johnson | Dec 29, 2023
It’s been a busy year in the cell and gene therapy community and the bloggers at Signals have enjoyed putting the spotlight on news (HeLa settlement and UK rejoins Horizon Europe), scientific advances (improving treatment for hematological malignancies and a new...
Comments